Stockscreener 앱 받기
0.00
100.00%
-63.48
시간 외 거래:
63.50
63.50
+
전일 마감가:
$63.48
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$11.52B
수익:
$4.42B
순이익/손실:
$-413.00M
주가수익비율:
0.00
EPS:
-2.27
순현금흐름:
$99.00M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$63.50
Catalent Inc Stock (CTLT) Company Profile
명칭
Catalent Inc
전화
(732) 537-6200
주소
14 SCHOOLHOUSE ROAD, SOMERSET, NJ
CTLT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTLT
Catalent Inc
|
0.00 | 11.52B | 4.42B | -413.00M | 99.00M | -2.27 |
|
ZTS
Zoetis Inc
|
160.46 | 71.85B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.08 | 45.58B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.58B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.74 | 19.18B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.60 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
Catalent Inc Stock (CTLT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-11-16 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2023-09-05 | 업그레이드 | Argus | Hold → Buy |
| 2023-07-20 | 개시 | Wells Fargo | Equal Weight |
| 2023-07-05 | 재개 | JP Morgan | Neutral |
| 2023-06-14 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-05-22 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-05-15 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-05-08 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-04-17 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2023-04-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-04-10 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2023-04-03 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-12-19 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-11-07 | 다운그레이드 | Argus | Buy → Hold |
| 2022-11-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-12-16 | 개시 | Barclays | Overweight |
| 2020-12-10 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-06-25 | 개시 | Argus | Buy |
| 2020-04-21 | 개시 | RBC Capital Mkts | Outperform |
| 2020-03-02 | 개시 | Deutsche Bank | Hold |
| 2019-10-17 | 재개 | Stephens | Overweight |
| 2019-08-28 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-06-21 | 업그레이드 | Jefferies | Hold → Buy |
| 2019-04-16 | 업그레이드 | UBS | Neutral → Buy |
| 2018-11-07 | 업그레이드 | First Analysis Sec | Neutral → Outperform |
| 2018-10-09 | 개시 | UBS | Neutral |
| 2018-03-28 | 업그레이드 | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-03-21 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-02-06 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2017-09-21 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-13 | 개시 | Needham | Hold |
| 2017-09-08 | 다운그레이드 | KeyBanc Capital Mkts | Overweight → Sector Weight |
| 2016-12-01 | 개시 | Goldman | Neutral |
| 2016-10-20 | 개시 | KeyBanc Capital Mkts | Overweight |
| 2016-06-21 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2016-06-20 | 업그레이드 | BofA/Merrill | Neutral → Buy |
모두보기
Catalent Inc 주식(CTLT)의 최신 뉴스
Catalent Appoints Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors - citybiz
Catalent Announces New Board Appointments - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Catalent, Inc. (CTLT) Investigation - ACCESS Newswire
Novo to grow Catalent? Rumor mill spins amid Trump tariff threat - BioProcess Insider
Jupiter Neurosciences partners with Catalent for Parkinson's trial - MSN
Ardena Acquires Catalent’s Drug Product Manufacturing Facility in Somerset, NJ - Contract Pharma
Ardena Completes Acquisition of Advanced Drug Product Manufacturing Facility from Catalent and Expands Bioanalytical Services in North America - Yahoo Finance
Jupiter Neurosciences Partners With Catalent For Parkinson's JOTROL Trial Production - Nasdaq
Jupiter Neurosciences Signs Manufacturing Deal With Catalent Pharma for Jotrol Softgel Capsules - Marketscreener.com
Jupiter Neurosciences Partners with Catalent to Produce JOTROL Softgels for Upcoming Clinical Trial - Contract Pharma
Jupiter Neurosciences partners with Catalent for Parkinson's trial By Investing.com - Investing.com South Africa
Jupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson's Trial - The Manila Times
Jupiter Neurosciences Announces JOTROL Manufacturing - GlobeNewswire
Major Breakthrough: New Parkinson's Drug Manufacturing Deal Could Fast-Track Treatment for 10M Patients - StockTitan
How Novo’s Acquisition Of Catalent Cleared European Regulators - Citeline
Catalent (CTLT) to Report Q2 Earnings: What's in the Cards? - MSN
Catalent (NYSE:CTLT) Now Covered by StockNews.com - Defense World
Pace Life Sciences Expands Capacity and Capability With Acquisition of Catalent’s Analytical Services Laboratory in Research Triangle Park - ACCESS Newswire
Catalent backs decentralised manufacture of Galapagos’ CAR-T therapy - MSN
Catalent to further expand Galapagos’ decentralized CAR-T manufacturing network in US - Indian Pharma Post
Catalent to support Galapagos’ decentralized cell therapy approach - The Pharma Letter
Catalent to Support Galapagos’ Decentralized CAR-T Therapy Trials - Contract Pharma
Catalent, Inc. (NYSE:CTLT) Given Average Rating of “Hold” by Analysts - Defense World
StockNews.com Begins Coverage on Catalent (NYSE:CTLT) - Defense World
Novo Holdings looks to double Catalent size with eye on Trump US manufacturing focus - Yahoo Finance
JPM 2025: Thermo Fisher ‘very positive’ on sterile demand as Catalent takes capacity out of market - Pharmaceutical Technology
Catalent (NYSE:CTLT) Now Covered by Analysts at StockNews.com - Defense World
Novo Holdings completes purchase of Catalent - MSN
Catalent (NYSE:CTLT) Coverage Initiated by Analysts at StockNews.com - Defense World
JPMorgan Chase & Co. Acquires 199,427 Shares of Catalent, Inc. (NYSE:CTLT) - Defense World
Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty - MSN
Federal Judge Clears Path for Texas-Led Antitrust Case Against Google - PYMNTS.com
Principal Financial Group Inc. Has $12.61 Million Position in Catalent, Inc. (NYSE:CTLT) - Defense World
Catalent, Inc. (NYSE:CTLT) Receives Consensus Rating of “Hold” from Brokerages - Defense World
Five Private Equity Deals That Helped Fuel Big Law in 2024 (1) - Bloomberg Law
Staff AccountantCatalent, Inc. - Built In
Novo Nordisk Set to Close Catalent Deal Without FTC Challenge - MSN
Novo Holdings completes $16.5 billion takeover of Catalent - MSN
Novo Holdings says its acquisition of Catalent is complete. - The Herald-Times
Novo Holdings Strengthens Pharma Standing With Catalent Acquisition - Finimize
Catalent, Inc Announces Board Changes - Marketscreener.com
Regulatory conditions on Novo Holdings' $16.5 billion Catalent deal fulfilled, companies say - MSN
Novo Holdings closes $16.5 billion buyout of contract manufacturer Catalent - MSN
Novo Holdings completes Catalent acquisition for $16.5bn - Yahoo Finance
Lennox To Join S&P 500 Index, Replacing Catalent - Yahoo! Voices
This industrials company is joining the S&P 500 soon - MSN
Novo Holdings completes $16.5B acquisition of Catalent - Inside INdiana Business
Novo Completes $16.5 Billion Acquisition of Catalent - Yahoo Finance
Novo Holdings Completes Acquisition of Catalent - citybiz
Catalent Inc (CTLT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.94%
0.51%
자본화:
|
볼륨(24시간):